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Abstract: Blockade of the renin–angiotensin system is an important approach in managing 
high blood pressure, and has increasingly been shown to affect cardiovascular disease processes 
mediated by angiotensin II throughout the cardiovascular and renal continua. Telmisartan is an 
angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including 
a longer half life than any other ARB, that result in large and sustained reductions of blood 
pressure. In patients with mild-to-moderate hypertension, telmisartan has proved superior 
to other antihypertensive agents (valsartan, losartan, ramipril, perindopril, and atenolol) in 
controlling blood pressure particularly towards the end of the dosing interval. There is also 
clinical evidence that telmisartan reduces left ventricular hypertrophy, reduces arterial stiffness 
and the recurrence of atrial fibrillation, and confers renoprotection. The ONgoing Telmisartan 
Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) study has 
demonstrated that telmisartan has similar cardiovascular protective effects to ramipril in a 
large, high-risk patient population but was better tolerated. The powerful and sustained blood 
pressure control apparent in clinical trials, together with cardiovascular protection and toler-
ability demonstrated in ONTARGET® means that telmisartan may be a preferred option for 
patients with hypertension.
Keywords: angiotensin II receptor blocker, cardiovascular disease, hypertension, renin–
angiotensin system, telmisartan
Introduction
Angiotensin II, which is generated by the renin–angiotensin system (RAS), plays a 
pivotal role in hypertension and cardiovascular disease. Thus, pharmacologic regu-
lation of angiotensin II is central to the control of blood pressure and prevention of 
its pathophysiologic effects on the cardiovascular system, including the kidney and 
the brain.
The angiotensin-converting enzyme (ACE) inhibitors target one of the enzymes 
that generate angiotensin II from angiotensin I (Figure 1). However, angiotensin II is 
not produced exclusively by this mechanism; other enzymes, such as chymase, are 
also able to generate angiotensin II.1 The angiotensin II receptor blockers (ARBs) 
overcome the detrimental effects of angiotensin II by preventing it binding to the 
type 1 receptors (AT1). This review examines evidence for the efficacy of telmisartan 
in the treatment of high blood pressure, and explores the body of the evidence that 
telmisartan prevents disease mediated by angiotensin II throughout the cardiovascular 
and renal continua.Vascular Health and Risk Management 2010:6 114
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Pharmacology of telmisartan
There are currently seven commercially available ARBs, with 
telmisartan offering unique pharmacologic features compared 
with the other agents of its class. Telmisartan displays insur-
mountable, but reversible binding to the AT1 receptor, and 
it has the highest binding affinity for this receptor among 
commercially available ARBs.2 As well as providing long-
term blockade of the AT1 receptor, telmisartan has minimal 
affinity for the AT2 receptor (K  10,000 nM) or for acetyl-
choline, catecholamine, dopamine, histamine, serotonin, or 
imipramine receptors.3 Telmisartan is also highly lipophilic, 
which facilitates oral absorption and benefits tissue and 
cell penetration, as demonstrated by its large volume of 
distribution of approximately 500 L,4,5 thereby blocking 
both systemic and local RAS. Unlike other ARBs, which 
are excreted to varying extents via the kidneys,6,7 more than 
90% of telmisartan is eliminated in the feces.8 An important 
distinguishing feature of telmisartan is its long terminal elimi-
nation half-life of about 24 hours, suggesting a long duration 
of action.5 It has been shown in healthy volunteers that, at 
peak plasma concentrations, telmisartan 80 mg reduces the 
response to exogenous angiotensin II by about 90%, and 
approximately 40% inhibition persists for 24 hours.9
Telmisartan modulates peroxisome proliferator-activated 
receptor γ (PPARγ), an established therapeutic target in the 
treatment of insulin resistance, diabetes, and metabolic 
syndrome.10 It has effects that are characteristic of PPARγ 
ligands on metabolism.11–14 In addition, there is a growing 
body of evidence that PPARγ activation raises adiponectin 
production and exerts anti-inflammatory, anti-oxidative and 
anti-proliferative effects on vascular walls, thus decreasing 
the risks for atherosclerosis.15,16 Although PPARγ activation 
has been reported for other commercially available 
ARBs,17–19 the effects on PPARγ activity have been shown 
to be considerably weaker than achieved with telmisartan 
and occur at much higher concentrations.19,20 Thus, the 
unique PPARγ-inducing properties of telmisartan, which are 
achievable at therapeutic doses, may have the capacity for 
targeting both diabetes and cardiovascular disease.
The importance of sustained blood 
pressure control
Hypertension is well recognized as a major risk factor 
for cardiovascular and renal morbidity and mortality. The 
importance of blood pressure lowering has been established 
through epidemiologic and clinical studies, and has led to 
a broad consensus from guideline bodies on the targets for 
blood pressure control. Improved control of blood pressure is 
vital to obtain maximum benefit.
Patients typically prefer to take their medication in 
the morning. To optimize patient compliance, once-
daily dosing is important. However, for a once-daily 
drug taken in the morning, early morning is the time of 
trough efficacy and may pose a problem in the manage-
ment of hypertension. In one study, approximately 60% 
of patients with apparently controlled hypertension when 
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Figure 1 Mechanism of blockade of the renin–angiotensin system.
Abbreviations: SNS, somatic nervous system; tPA, tissue plasminogen activator.Vascular Health and Risk Management 2010:6 115
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measured in the office during the day had, in reality, 
uncontrolled blood pressure (systolic blood pressure [SBP]/
diastolic blood pressure [DBP]  130/85 mmHg) determined 
by ambulatory blood pressure monitoring (ABPM) in the 
early morning.21 An antihypertensive agent’s duration of 
action must be sufficient to control blood throughout the 
dosing interval and, ideally, if the next dose is delayed or 
missed.22
A further consideration is that, during the morning, 
incidences of cardiovascular events increase dramatically and 
are more frequent than at any other time of the day.23–25 Blood 
pressure follows a circadian rhythm, being lowest at night 
and increasing suddenly in the morning upon awakening.26 
This early morning blood pressure surge (EMBPS) is caused 
primarily by orthostatic changes but is also linked to circadian 
changes in the RAS.27–29
Antihypertensive efficacy 
of telmisartan
The efficacy of telmisartan in the primary care setting has 
recently been demonstrated in the MICARDIS® Community 
Access Trial (MICCAT-2) involving 1619 patients.30 The 
patients had uncontrolled hypertension, 675 having blood 
pressure that was not controlled despite prior receipt of 
conventional therapy. The patients in the trial were treated 
with telmisartan 40 mg, titrated to 80 mg or a combination of 
telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg. 
Office SBP/DBP fell by 22.7/12.6 mmHg in the previously 
untreated patients and by 16.8/10.3 mmHg in the previously 
treated patients. After telmisartan treatment, blood pressure 
was controlled in 79% of the patients.
An accurate reflection of the extent of blood pressure 
control at different stages of the dosing interval is provided by 
self-measurement of  blood pressure in the home or by 24-hour 
ABPM using an automated device.31 In MICCAT-2, ABPM 
showed that telmisartan alone or in combination with HCTZ 
produced significant reductions in blood pressure as shown in 
both day-time and night-time mean SBP/DBP. Furthermore, 
telmisartan reduced SBP/DBP by 17.2/10.1 mmHg in the 
4 hours post-awakening in the 95 patients who had an 
EMBPS of SBP  30 mmHg.32
A large number of clinical studies have demonstrated 
the antihypertensive efficacy of telmisartan versus other 
antihypertensive agents. Key studies, as described below, 
are summarized in Table 1. It should be noted that relative 
efficacy in fixed-dose studies depends upon the doses 
employed, which typically related to the doses approved or 
intended for clinical practice when the study was conducted. 
Results should be interpreted with caution in cases where the 
doses employed are less than the current, clinically-available 
maximal dose.
Telmisartan versus other ARBs
In Japanese hypertensive patients, home blood pressure 
measurement confirmed that telmisartan reduces blood 
pressure more than other ARBs.33 At the lower doses typically 
used in Japan, once-daily telmisartan 10 to 40 mg taken in 
the morning achieved greater blood pressure reductions in 
the early morning than once-daily valsartan 40 to 80 mg, 
candesartan 2 to 12 mg, or losartan 25 to 100 mg. Comparison 
of the morning effect on blood pressure versus the evening 
effect on blood pressure showed that, in particular, the effect 
of losartan did not persist for 24 hours.
Ambulatory blood pressure monitoring has shown that 
telmisartan 80 mg confers significantly greater blood pres-
sure lowering than several other ARBs. When compared 
with valsartan 160 mg, telmisartan provided sustained anti-
hypertensive efficacy and superior control of blood pressure 
during the early morning period.34,35 Differences between the 
treatments were also apparent for seated SBP. This measure 
was significantly reduced by telmisartan compared with 
valsartan (12.1 vs 8.2 mmHg, respectively; P = 0.0281), 
while the reduction in DBP was also numerically greater 
with telmisartan.35 Pooled data from two studies showed that, 
after active therapy, last 6-hour mean DBP was reduced by 
7.6 mmHg with telmisartan compared with 5.8 mmHg with 
valsartan (P = 0.0044) and last 6-hour mean SBP was reduced 
by 11.1 mmHg with telmisartan as opposed to 9.1 mmHg 
with valsartan (P = 0.0066).35 After a dose was deliberately 
missed, 24-hour mean DBP was reduced by 7.2 mmHg 
with telmisartan compared with 5.5 mmHg with valsartan 
(P = 0.0004), and the reduction in 24-hour mean SBP after a 
missed dose was 10.7 mmHg with telmisartan and 8.7 mmHg 
with valsartan (P = 0.0024).
Similarly, 3 ABPM studies comparing telmisartan 40 or 
80 mg with losartan 50 or 100 mg demonstrated that telmis-
artan provided greater reductions than losartan in both the 
24-hour mean SBP and DBP and in the in last 6 hours of 
the dosing interval.36–38
There are fewer data comparing the antihypertensive 
efficacy of telmisartan with ARBs other than valsartan and 
losartan. A 1-year comparative study in patients with mild 
hypertension and type 2 diabetes showed that telmisartan 
produced a superior reduction in blood pressure compared 
with eprosartan.39 Two small-scale clinical studies have 
compared the blood pressure lowering effects of telmisartan Vascular Health and Risk Management 2010:6 116
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40 mg versus olmesartan 20 mg in Japanese patients. 
In one open-label study of 20 patients with early-stage 
type 2 diabetes and hypertension, olmesartan was shown to 
provide greater blood pressure reductions than telmisartan.40 
Conversely, in a separate study, telmisartan was shown to 
be more effective than olmesartan for controlling early 
morning blood pressure, in addition to improving glucose 
and cholesterol levels in patients with hypertension, chronic 
heart failure and metabolic syndrome.41 A PubMed search 
identified no clinical trials directly comparing the antihyper-
tensive effects of telmisartan versus irbesartan.
Telmisartan versus ACe inhibitors
Other evidence for telmisartan providing effective blood 
pressure control comes from two 14-week studies of identi-
cal design – Prospective, Randomized Investigation of the 
Safety and efficacy of MICARDIS® versus ramipril using 
ABPM (PRISMA™) – conducted in 1613 hypertensive 
patients in Europe and South Africa (PRISMA™ I) and 
in the USA and Canada (PRISMA™ II). In PRISMA™ I, 
telmisartan titrated from 40 to 80 mg and given in the morn-
ing provided superior blood pressure control than ramipril 
titrated from 2.5 to 5 to 10 mg.42 Notably, this difference 
was observed throughout all periods of the 24-hour dosing 
interval and resulted in significantly greater reduction in 
SBP/DBP than ramipril during the last 6 hours (P  0.001).42 
Similar results were recorded in PRISMA™ II.43 The pooled 
analysis of the PRISMA™ I and II trials documented that 24-h 
mean SBP/DBP reductions were significantly greater with 
telmisartan than ramipril (-14.1/-9.6 vs -11.1/-7.2, respec-
tively) and superiority of telmisartan over ramipril was also 
apparent during the last 6 hours (difference: 4.8/3.3 mmHg 
(P  0.0001)).44 Furthermore, the findings of a meta-analysis 
of individual data from 1 million patients in 61 prospec-
tive studies suggest that the statistically significant greater 
reduction in last 6-hour mean SBP in patients treated with 
telmisartan in the PRISMA™ studies is of clinical relevance 
in improving long-term prognosis.45
The antihypertensive effect of telmisartan was examined 
in a double-blind comparison of telmisartan 80 mg and per-
indopril 4 mg. Both agents produced similar reductions in 
24-hour mean SBP/DBP at the end of the 8-week study.46 
However, telmisartan provided significantly greater reduc-
tions in hourly mean DBP in each of the last 8 hours of 
the dosing period. Telmisartan 40 mg was also compared 
with perindopril 4 mg in a 12-week, open-label study, with 
the dose being doubled in patients who failed to respond 
(DBP  90 mmHg) at week 6.47 Reductions in trough 
SBP/DBP from baseline were significantly greater with 
telmisartan at both 6 and 12 weeks.
Using both 24-hour ABPM and clinic blood pressure 
measurements, telmisartan 80 mg was found to be as effective 
as lisinopril 20 mg in reducing SBP and DBP, with telmis-
artan provide sustained blood pressure control throughout 
the 24-hour dosing interval.48 Higher doses of telmisartan 
(40, 80, and 160 mg) and lisinopril (10, 20, and 40 mg) 
were compared in another, larger titration-to-response study 
measuring trough clinic blood pressure and comprising 
578 patients who could also receive HCTZ up to a dose of 
25 mg.49 Control of DBP was similar in patients receiving 
either telmisartan or lisinopril.
As well as telmisartan generally producing greater 
reductions in SBP and DBP that were particularly evident 
towards the end of the dosing period, telmisartan is better 
tolerated than ACE inhibitors. Comparative studies have 
consistently shown that incidences of cough were lower 
with telmisartan than with perindopril,46,47 lisinopril,49 
or ramipril.42,43 The ONgoing Telmisartan Alone and in com-
bination with Ramipril Global Endpoint Trial (ONTARGET®) 
study, which was an outcome study in a broad cross-section 
of patients who were at high risk for cardiovascular diseases 
and who could tolerate ACE inhibitors, the rates of cough 
and angioedema were significantly lower with telmisartan 
than with ramipril.50 Moreover, telmisartan was associated 
with better tolerability and greater treatment adherence. The 
differences in tolerability and adherence between telmisartan 
and ramipril may well have implications for patients who need 
long-term treatment to reduce their cardiovascular risk.
Telmisartan versus beta (β)-blockers
Beta-blockers have been compared with telmisartan in 
several studies of short or longer duration. In a titration-to-
response study of 533 patients (with HCTZ added as needed 
to achieve blood pressure control; mean baseline seated 
BP 165.8/101.8 mmHg), full SBP response (89 mmHg 
and/or 10% reduction from baseline) was achieved by 
84% of telmisartan-treated patients and 78% of atenolol-
treated patients (nonsignificant).51 In addition, 80% achieved 
a 10 mmHg reduction in trough SBP with telmisartan 
40 to 80 to 120 mg compared with only 68% of patients 
receiving atenolol 50 to 100 mg (P = 0.003).51 In addition, 
telmisartan had the advantage of being better tolerated: over 
the 26-week study, side effects were experienced by 53% of 
patients receiving telmisartan but by 61% of those treated 
with the β-blocker. Most notably, there were fewer incidences 
of fatigue and male impotence. The superiority of telmisartan Vascular Health and Risk Management 2010:6 123
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was also demonstrated in an 8-week open-label comparison 
of telmisartan 80 mg and atenolol 50 mg in 58 patients.52
Telmisartan was compared with carvedilol in a multicenter 
study on their effects on left ventricular mass (LVM) in 
patients with mild-to-moderate hypertension.53 As part of the 
study, ABPM was performed at baseline and after 44 weeks’ 
treatment with telmisartan 80 mg or carvedilol 25 mg in 
82 patients. The 24-hour mean SBP/DBP reductions were 
similar in both treatment groups. However, night-time and last 
6-hour mean reductions were numerically greater with telmis-
artan, although statistical significance was not achieved.
Telmisartan versus calcium 
channel blockers
When telmisartan 40 mg (titrated to 80 mg at 4 weeks 
and to 120 mg at 8 weeks for patients whose DBP 
remained 90 mmHg) and amlodipine 5 mg (5 mg at 
4 weeks to 10 mg at 8 weeks for patients whose DBP 
remained 90 mmHg)54 were compared, ABPM demonstrated 
that both agents produced similar, significant decreases in 
24-hour mean SBP/DBP (P  0.0001). Telmisartan, however, 
was superior to amlodipine with respect to the reductions in 
DBP at night and during the early morning hours: reduction 
in DBP in the last 4 hours of the dosing interval was 
3.4 mmHg greater with telmisartan than with amlodipine 
(P  0.05). In addition, a 24-hour mean DBP  85 mmHg 
were observed in 71% of telmisartan-treated patients but 
only in 55% of those receiving amlodipine. Telmisartan 
was also better tolerated: the incidence of adverse events, 
particularly edema, was lower with telmisartan (5%) than 
with amlodipine (22%; P = 0.05).
Another 12-month study, primarily designed to evaluate 
left ventricular hypertrophy (LVH), compared the antihyper-
tensive efficacy of telmisartan 40 mg with that of nifedipine 
gastrointestinal therapeutic system (GITS) 20 mg.55 Similar 
and significant reductions from baseline in SBP/DBP were 
observed in the two treatment arms.
Telmisartan versus HCTZ
Telmisartan has been shown to provide more effective 
control of high blood pressure than HCTZ. In an 8-week 
factorial study comparing telmisartan (20, 40, 80, or 160 mg), 
3 doses of HCTZ (6.25, 12.5, or 25 mg) and combinations 
of these doses, telmisartan 40 and 80 mg resulted in greater 
reductions in SBP and DBP than HCTZ 12.5 mg.56
In a 12-month study to determine the effect of telmis-
artan and HCTZ on LVH in hypertensive patients, 24-hour 
ABPM was performed at baseline and after 12 months’ 
double-blind treatment with telmisartan 80 mg or HCTZ 
25 mg.57 At the end of the study, significant reductions from 
baseline in 24-hour mean SBP/DBP were detected in both 
treatment groups, but the blood pressure-lowering effect of 
24/13 mmHg with telmisartan versus 10/8 mmHg with HCTZ 
was significantly superior (P  0.01).
Another study was performed in 1039 patients with isolated 
systolic hypertension.58 Trough office SBP was reduced 
by 15.6 mmHg and 17.9 mmHg in the telmisartan 40 and 
80 mg arms after 6 weeks, respectively. This lowering was 
similar to that of 15.7 mmHg recorded with HCTZ 12.5 mg. 
However, significantly more patients achieved the target 
reduction in SBP (140 mmHg or 20 mmHg reduction) 
with telmisartan 80 mg than with HCTZ 12.5 mg (P = 0.03).
Combination treatment in difficult-to-
treat patients and high-risk populations
Blood pressure in some patients is ineffectively controlled 
with monotherapy, and they require a combination of anti-
hypertensive agents to achieve target blood pressure. The 
combination of telmisartan and HCTZ has been shown to 
provide greater reductions in blood pressure than either com-
ponent alone. After a 4-week, placebo run-in period, patients 
were randomized to receive placebo, telmisartan 20, 40, 80 or 
160 mg/day, HCTZ 6.25, 12.5 or 25 mg/day, or one of 12 com-
binations of the two agents in a trial involving 818 patients 
with mild-to-moderate hypertension.56 The analysis focused 
on two combinations: telmisartan 40 mg/HCTZ 12.5 mg and 
telmisartan 80 mg/HCTZ 12.5 mg. After 8 weeks, telmisartan 
80 mg/HCTZ 12.5 mg significantly reduced mean supine 
trough blood pressures by 23.9/14.9 mmHg compared 
with placebo, which represented a 8.5/3.4 mm Hg greater 
decrease than that achieved with telmisartan 80 mg alone 
and a 17.0/7.7 mmHg greater decrease than HCTZ 12.5 mg 
alone (both P  0.01). There was a significant reduction in 
SBP of 18.8 mmHg with telmisartan 40 mg/HCTZ 12.5 mg 
compared with placebo, and this decrease was significantly 
greater than that achieved with either monotherapy.
Data from two studies evaluating the combination of 
telmisartan and HCTZ showed that it produced significantly 
greater SBP and DBP reductions in the last 6 hours of the dos-
ing interval compared with losartan/HCTZ.59 Two studies of 
identical design have also shown that the fixed-dose combina-
tion of telmisartan 80 mg/HCTZ 25 mg lowered trough blood 
pressure to a greater extent than valsartan 160 mg/HCTZ 
25 mg in patients with stages 1 and 2 hypertension.60,61 
In a comparison of telmisartan 80 mg/HCTZ 12.5 mg with 
olmesartan 20 mg/HCTZ 12.5 mg, the telmisartan/HCTZ Vascular Health and Risk Management 2010:6 124
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combination gave a greater reduction in 24-h blood pressure, 
and this difference was also seen in daytime and night-time 
blood pressure values.62
There have been several studies that have investigated 
the combination of telmisartan and HCTZ in patients whose 
blood pressure is not adequately controlled by telmisartan 
alone. In one such study, patients whose DBP remained 
above 90 mmHg after 8 weeks of treatment with telmisartan 
80 mg were randomized to telmisartan 80 mg or telmisar-
tan 80 mg/HCTZ 12.5 mg for a further 8 weeks.63 Greater 
reductions in blood pressure were achieved with the combina-
tion, such that blood pressure had been normalized (defined 
as SBP  140 mmHg and DBP  90 mmHg) in 41.5% of 
patients receiving the combination versus 26.1% of patients 
receiving monotherapy.
Patients who are at a particular risk of cardiovascular 
disease include those who are obese or have type 2 diabetes. 
It often proves especially difficult to achieve the rigorous 
control of blood pressure required in these patients. Superior 
blood pressure lowering of telmisartan 80 mg plus HCTZ 
12.5 mg, compared with valsartan 160 mg/HCTZ 12.5 mg 
over 24 hours and during the early morning hours was dem-
onstrated in the Study of MICARDIS® on Obese/Overweight 
Type 2 diabetics with Hypertension (SMOOTH®).64
The elderly, another group in which it can be difficult to 
achieve satisfactory blood pressure control, were recruited 
into ATHOS® (A comparison of  Telmisartan plus HCTZ with 
amlodipine plus HCTZ in Older patients with predominantly 
Systolic hypertension). In 1000 patients (60 years) with 
isolated systolic hypertension, telmisartan 40 to 80 mg plus 
HCTZ 12.5 mg was compared with amlodipine 5 to 10 mg 
plus HCTZ 12.5 mg.65 Although there was no significant 
difference between the two groups in the change from 
baseline in SBP during the last 6 hours of the dosing inter-
val (which was the primary end point), telmisartan/HCTZ 
resulted in significantly greater reductions in 24-hours, 
morning and daytime SBP than amlodipine/HCTZ. The 
ATHOS study indicates that the combination of telmisartan 
plus HCTZ provides effective blood pressure control in 
elderly patients.
A common finding of these studies was that the placebo-
like tolerability profile of telmisartan was maintained when 
it was given in combination with HCTZ. In an analysis of 
50 trials involving 16,416 patients, the overall incidence 
of adverse events was low and similar between telmisartan 
monotherapy and the telmisartan/HCTZ combination.66
The combination of telmisartan and amlodipine has also 
been demonstrated to provide more powerful reductions in 
blood pressure than monotherapy with either telmisartan 
or amlodipine.67 In a factorial design study, patients with 
stage 1 or 2 hypertension received placebo, telmisartan 
(20 to 80 mg), amlodipine (2.5 to 10 mg) or a combination 
of the two agents. The reductions in the in-clinic DBP and 
SBP observed with the combinations of most clinical interest 
(40 or 80 mg plus amlodipine 5 or 10 mg) were all significant. 
The greatest overall reductions (-26.4/-20.1 mmHg) were 
achieved with the telmisartan 80 mg/amlodipine 10 mg 
combination. This was also associated with the greatest 
response rates and blood pressure control. In the study, the 
treatments were well tolerated and, notably, the high incidence 
of edema with amlodipine 10 mg monotherapy (17.8%) 
was reduced by 37% to 65% when telmisartan was used in 
combination.68 Therefore, the combination of telmisartan and 
amlodipine represents a treatment option that delivers large 
reductions in blood pressure and thereby likely reducing 
the risk of cardiovascular events.
Cardiovascular protective effects 
of telmisartan
The concept of the cardiovascular and renal continua was 
introduced to explain the pathologic processes connecting 
risk factors to clinical events of increasing severity and ulti-
mately resulting in end-organ damage and death (Figure 2). 
Hypertension is one such risk factor. There is a large body of 
evidence, from ex vivo and in vivo studies to demonstrate that 
modulation of the RAS with ARBs and ACE inhibitors inter-
feres with several of the pathophysiological mechanisms that 
lead to target organ damage (TOD), which, if uncontrolled, 
can be life-threatening.
The cardioprotective properties of ARBs have yet to be 
determined for all agents in this class and direct compari-
sons on the effects of ARBs on target organ protection are 
sparse. Furthermore, within-class comparisons are made 
difficult given that cardiovascular outcome studies of ARBs 
have been conducted in very different patient populations, 
ranging from low risk patients with hypertension (eg, the 
Losartan Intervention For Endpoint reduction in hyperten-
sion [LIFE]69 and Valsartan Antihypertensive Long-term 
Use Evaluation [VALUE]70 trials) through to patients with 
severe underlying cardiovascular disease (eg, the Valsartan 
Heart Failure Trial [ValHeFT],71 Candesartan in Heart 
Failure Assessment of Reduction in Mortality and morbidity 
[CHARM] trial,72 and Valsartan in Acute Myocardial 
Infarction Trial [VALIANT]).73
Current evidence focusing on telmisartan suggest that 
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dysfunction, reductions in LVH, renoprotection in normotensive 
and hypertensive subjects, improvements in metabolic param-
eters, and potential benefits in cerebrovascular disease, 
as discussed below.
Telmisartan and endothelial function
One mechanism by which telmisartan may prevent TOD is 
by reducing or reversing endothelial dysfunction, which is 
one of the first signs of vascular damage and is partly driven 
by oxidative stress.74 Telmisartan reduced superoxide 
production, nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activity, and markers of oxidative stress 
in apolipoprotein E-deficient mice.75 In addition, telmisartan 
decreased the size of atherosclerotic lesions.75 In spontane-
ously hypertensive rats, telmisartan expression of NADPH 
oxidase is reduced and there was increased expression of 
endothelial nitric oxide synthase, which is likely to contribute 
to reduced oxidative stress.76
Oxidative stress also promotes the accumulation of 
advanced glycation end (AGE) products.77 Together with their 
cell-surface receptor (RAGE), AGEs are a major cause of the 
microvascular damage that accompanies the hyperglycemia 
of diabetes. In cultured endothelial cells, telmisartan prevents 
angiotensin II-induced upregulation of RAGE expression.78 
Corroboration for this effect is provided by studies in 
telmisartan-treated spontaneously hypertensive rats in which 
the RAGE expression that would normally accompany intra-
ocular age expression did not occur.79
Platelet-derived growth factor (PDGF) is a mitogen that 
is upregulated by oxidative stress and inflammatory stimuli.80 
It is known to be produced by smooth muscle cells and is 
one of the most potent growth factors that is involved in 
the progression of macroangiopathy as seen in diabetes. 
Telmisartan has been shown to reduce angiotensin II-induced 
oxidative stress and thereby suppressed the expression of 
PDGF-B in cultured bovine retinal pericytes.81,82
Clinical evidence for improvements in endothelial func-
tion with telmisartan is provided by the Telmisartan versus 
Ramipril in renal ENdothelial DYsfunction (TRENDY®) 
study.83 Both telmisartan 40 mg and ramipril 5 mg improved 
endothelial function, assessed by measuring renal plasma 
flow in response to the infusion of NG-monomethyl-l-arginine 
acetate (l-NMMA), in patients with mild-to-moderate hyper-
tension and normo- or microalbuminuria. Another measure 
of endothelial function, brachial artery flow-mediated 
dilation, was improved by 36% by ramipril 2.5 mg, 96% by 
telmisartan 40 mg, and by 111% with the combination in 
nonhypertensive patients with well-controlled type 2 diabetes 
mellitus, but without coronary artery disease, left ventricular 
dysfunction, or microalbuminuria.84
Figure 2 The cardiovascular and renal continua of disease and studies evaluating the efficacy of telmisartan.
Abbreviations: ARB, angiotension II receptor blocker; FDC, fixed-dose combination; LVH, left ventricular hypertrophy.Vascular Health and Risk Management 2010:6 126
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Telmisartan and arterial stiffness
Arterial stiffness is an important risk factor for cardiovascular 
mortality85 and is increased on acute infusion of angiotensin II.86 
Prior administration of telmisartan significantly attenuated 
this acute response, as indicated by changes in systemic 
vascular resistance and the pulse wave stiffness index.87 
Furthermore, in patients with type 2 diabetes and mild-
to-moderate hypertension, telmisartan 40 mg for 3 weeks 
reduced arterial stiffness measured by pulse wave velocity 
along the carotid–femoral route.88 Another study in patients 
with hypertension suggests that the improvement in pulse 
wave velocity is greater than predicted on the basis of blood 
pressure changes.89
Metabolic effects of telmisartan
Vascular risk factors of hypertension, hyperglycemia, and 
atherogenic dyslipidemia are prevalent abnormalities in 
subjects with type 2 diabetes. Diabetes increases cardiovas-
cular risk to the same extent as a prior myocardial infarction 
(MI) in a nondiabetic subject.90
Studies in hypertensive patients have shown consistently 
that telmisartan improves insulin sensitivity and lipid profiles. 
For example, in patients with type 2 diabetes (managed with 
diet and exercise) and mild hypertension, telmisartan 40 mg 
was significantly more effective than eprosartan 600 mg in 
reducing low-density lipoprotein (LDL)-cholesterol, total 
cholesterol, and triglycerides.39 In another study conducted in 
patients with type 2 diabetes treated with oral hypoglycemics, 
telmisartan 40 mg produced significantly greater reductions 
than nifedipine GITS 20 mg in LDL-cholesterol and total 
cholesterol.55 The effects of telmisartan on lipid parameters 
have been also been observed in smaller study91 and in a 
post-marketing surveillance study in which people with and 
without diabetes were treated with telmisartan 40 to 80 mg 
for at least 1 year.92 In the latter study, triglycerides were 
reduced by 17.4 mg/dL and cholesterol by 16.4 mg/dL in the 
population as a whole and were 22.7 mg/dL and 23.8 mg/dL, 
respectively, in patients with hypercholesterolemia. Among 
patients with diabetes, the reductions were 22.7 mg/dL and 
17.4 mg/dL, respectively.
Telmisartan has been demonstrated to improve markers 
of glycemic control, such as glycosylated hemoglobin93,94 and 
insulin91 in patients with type 2 diabetes. Reductions in insulin 
resistance with telmisartan have also been demonstrated in 
nondiabetic subjects.95,96 Moreover, telmisartan 80 mg 
lowered insulin resistance, as measured by the homeostasis 
model assessment method, to a significantly greater extent 
than losartan 50 mg in hypertensive patients with metabolic 
syndrome.97 Free plasma glucose, glycosylated hemoglobin 
and response to the oral glucose tolerance test were also 
significantly improved by telmisartan.
Telmisartan in renal impairment
The progression of renal disease can be halted by RAS 
blockade mediated through reductions in glomerular pressure 
and through decreased inflammation and oxidative stress. 
Evidence for the renoprotective effect of telmisartan comes 
from studies that together have demonstrated positive benefits 
on renal function in the renal continuum from endothelial 
dysfunction through to reductions in macroalbuminuria.
In the TRENDY® study, telmisartan not only improved 
renal endothelial function in patients with type 2 diabetes but 
also preserved renal function.83 In comparison with ramipril, 
telmisartan significantly improved resting renal plasma 
flow, renal vascular resistance, and lowered albuminuria.
The Diabetics Exposed to Telmisartan And enalaprIL 
(DETAIL®) study showed the long-term benefit of telmisartan 
in patients with type 2 diabetes and either micro- or macro-
albuminuria.98 Glomerular filtration rate (GFR) declined in 
the first year with both treatments, but this effect has also 
been observed with ACE inhibitors and other ARBs, and has 
been attributed to a hemodynamic effect.99,100 Thereafter, the 
rate of decline was markedly reduced, such that by year 3, 
the annual decline in GFR had stabilized to approximately 
2 mL/min/1.73 m2, which is substantially lower than the 
10 to 12 mL/min/1.73 m2 that is typical in untreated diabetics 
with macroalbuminuria.101
Telmisartan has also been shown to reduce albuminuria 
compared with HCTZ in nondiabetic patients with isolated 
systolic hypertension102 and to reduce microalbuminuria 
by 69% over the course of a 12-month, noncomparative 
study in hypertensive patients.103 Other studies confirmed 
that telmisartan reduced macroalbuminuria in patients with 
mild and moderate renal failure.104,105 The effects of telmis-
artan on proteinuria may well be additive to those of ACE 
inhibitors.106
Several large-scale clinical studies have been completed 
that demonstrate the beneficial effects of telmisartan on renal 
function. The Incipient to Overt: Angiotensin II Blocker, 
Telmisartan, Investigation on Type 2 Diabetic Nephropathy 
(INNOVATION®) study was performed in normotensive, as 
well as in hypertensive, Japanese patients.107 Over a mean 
of 1.3 years’ treatment, both telmisartan 40 and 80 mg 
significantly reduced transition rates to overt nephropathy in 
comparison with placebo. Reduced transition rates to overt 
nephropathy remained after adjustment for changes in SBP Vascular Health and Risk Management 2010:6 127
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and in normotensive patients, suggesting telmisartan had a 
blood pressure-independent effect.
The sister studies, A trial to compare telMisartan 40 mg 
titrated to 80 mg versus losArtan 50 mg titrated to 100 mg in 
hypertensive type 2 DiabEtic patients with Overt nephrop-
athy (AMADEO™), and inVestigate the efficacy of 
MICARDIS® versus VALsartan in hypertensive type 2 DIabetic 
patients with overt nephropathy (VIVALDI®) evaluated the 
effect of telmisartan on macroalbuminuria. In AMADEO™, 
telmisartan reduced urinary protein:creatinine significantly 
more than losartan after 52 weeks (29% versus 20% from 
baseline, respectively; P = 0.03), despite similar blood 
pressure control.108 This suggests that there are intra-class 
difference in the renal effects of ARBs, which is consistent 
with additional properties beyond the blood pressure-
lowering effect. In VIVALDI®, telmisartan 80 mg provided 
identical reductions in urinary protein excretion (33% from 
baseline) to valsartan 160 mg and there were no significant 
differences between the two agents in serum creatinine, 
creatinine clearance, or estimated GFR changes.109 These 
studies suggest that telmisartan may slow the progression 
of diabetic nephropathy in this group of patients.
Cardiac disease
The presence of LVH in patients with established hyperten-
sion nearly triples the incidence of coronary heart disease 
and stroke, and increases the incidence of heart failure 
about seven-fold.110 Reducing LVM significantly reduces 
cardiovascular risk.111 Angiotensin II plays a central role 
in cardiac hypertrophy, causing a trophic response to 
increased blood pressure and having direct proliferative 
effects.112 The clinical evidence that telmisartan reduces 
LVM comes from several studies. For example, telmisartan 
reduced LVM from 151.6 to 135.1 g/m2, largely due to 
decreased thickness of the left ventricular wall, in hyper-
tensive patients.113 Telmisartan has been compared with 
other antihypertensives, including diuretics, β-blockers, 
ACE inhibitors, and other ARBs. Telmisartan 80 mg 
proved superior to HCTZ 25 mg, with the reduction in 
LVM being significantly greater with telmisartan for a 
given percentage change in blood pressure.57 Telmisartan 
80 mg was more effective in reducing LVM than carvedilol 
25 mg, despite there being no significant difference in 
24-hour mean SBP/DBP reductions between the two treat-
ments.53 Addition of telmisartan 80 mg to ramipril 5 mg 
provided further beneficial effects on LVM, although 
there were similar reductions in blood pressure with either 
monotherapy or combination.114
A 12-week study showed that replacing twice-daily 
enalapril 10 mg with once-daily telmisartan 10 to 80 mg does 
not produce any acute deterioration of exercise capacity or 
clinical status in patients with mild-to-moderate congestive 
heart failure (CHF) (New York Heart Association [NYHA] 
Class II or III and left ventricular ejection fraction 40%).115 
The study also found no differences in changes of other 
parameters, such as ejection fraction, NYHA classification, 
and mean SBP between the treatment groups.
Atrial fibrillation
ARBs and ACE inhibitors have been shown to be effective 
in preventing atrial fibrillation in patients with heart failure 
or left ventricular dysfunction, as seen in the meta-analysis 
by Healey and colleagues.116 The RAS plays an important 
role facilitating new onset or recurrence of atrial fibrillation. 
It mediates atrial remodeling by increasing blood pressure, 
intracavitary atrial pressure, and arrhythmogenic atrial 
remodeling, by facilitating coronary atherosclerosis and 
by increasing reactive oxygen substances and favoring 
atrial fibrosis. Blocking the RAS may prevent left atrial 
dilatation, atrial fibrosis, dysfunction, and conduction 
velocity slowing.
There are different clinical scenarios involving prevention 
of atrial fibrillation in the hypertensive patient (ie, those who 
have not had any previous episodes of atrial fibrillation, and 
those with parossistic or persistent atrial fibrillation who 
either do not need any anti-arrhythmic therapy, or those with 
persistent atrial fibrillation who do require anti-arrhythmic 
therapy to maintain sinus rhythm following cardioversion). 
Previous studies suggest that inhibition of RAS with ARBs 
or ACE inhibitors may prevent new onset atrial fibrillation in 
patients without any previous episodes of atrial fibrillation,117 
and recurrence after cardioversion in hypertensive patients 
requiring antiarrhythmic therapy.118 Previously, we investi-
gated whether telmisartan prevented the recurrence of atrial 
fibrillation in hypertensive patients who did not require anti-
arrhythmic therapy. We compared the efficacy of telmisartan 
and carvedilol in preventing the recurrence of atrial fibril-
lation in 154 hypertensive patients with a recent history of 
atrial fibrillation.119 There was an atrial fibrillation episode 
in 14.2% (10/70) of patients who received telmisartan 
compared with 37% (23/62) of those receiving carvedilol 
(P  0.005). In addition to preventing recurrence of atrial 
fibrillation, the time to a recurrence of atrial fibrillation was 
longer with telmisartan than with carvedilol. This difference 
in the rates of new episodes of atrial fibrillation between the 
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size, although a greater left ventricular mass reduction in the 
telmisartan group was observed. This suggests preventive 
properties of telmisartan were a pharmacologic effect. It is 
possible that telmisartan favorably interferes with electrical 
and structural atrial remodeling in hypertensive patients.
Cerebrovascular disease
For each 2 mmHg increase in SBP, the risk of stroke is 
increased by 10%.45 Angiotensin II pathways appear not only 
to be implicated in blood pressure control and body fluid 
homeostasis, but may also contribute to the pathogenesis 
of stroke via the stimulation of AT1 receptors.120 The use 
of ARBs may not only prevent the ischemic effect of 
angiotensin II mediated via AT1 receptors, but also stimulate 
the unoccupied AT2 receptors with a consequent improve-
ment of brain ischemia. Intra-cerebroventricular infusion 
of an ARB for 5 days has been shown to induce neuronal 
regrowth after cerebral ischemia and to reduce expression of 
transcription factors c-Fos and c-Jun that are associated with 
programmed cell death and neurodegeneration.121 To date, 
evidence of possible beneficial effects of telmisartan on 
cerebrovascular disease are provided by studies in animals.
In rats, telmisartan is able to cross the blood–brain 
barrier and block the effects of centrally administered 
angiotensin II.122 Furthermore, at doses that had no effect 
on blood pressure, telmisartan delayed the onset of stroke 
in spontaneously hypertensive, stroke-prone animals.123 
In cerebral arterioles, telmisartan reversed the vasoconstrictor 
effect of angiotensin II, changing the response to a vasodi-
latory one124 and overcame the cerebral arterial remodeling 
occurring in spontaneously hypertensive rats.125
Although the effect of telmisartan on stroke has yet to be 
demonstrated in clinical studies, the effects of telmisartan on 
cognitive function have been examined in elderly subjects 
with hypertension.126 In addition to providing superior blood 
pressure control compared with lisinopril 20 mg plus HCTZ, 
telmisartan 80 mg given with HCTZ 12.5 mg improved 
performance on cognitive tests significantly more than 
lisinopril/HCTZ.
Telmisartan outcome trials
The ONTARGET® program consists of two long-term, large-
scale, double-blind, multinational outcome studies – the 
ONTARGET® study50 and the parallel Telmisartan Random-
ized AssessmeNt Study in aCE iNtolerant subjects with 
cardiovascular Disease (TRANSCEND®) study.127
The ONTARGET® study compared telmisartan 80 mg 
monotherapy to ramipril 10 mg monotherapy and the 
combination to ramipril alone. The primary endpoint was a 
composite of cardiovascular mortality, nonfatal MI, nonfatal 
stroke, and hospitalization for CHF. Secondary endpoints 
included newly diagnosed CHF, cardiovascular revascu-
larization, newly diagnosed diabetes, cognitive decline/
dementia, new onset of atrial fibrillation, and nephropathy. 
ONTARGET® was conducted in patients who could tolerate 
ACE inhibitor therapy, whereas TRANSCEND® compared 
telmisartan with placebo in addition to best standard of care 
in patients intolerant of this class using the same endpoints 
as ONTARGET®.
In the ONTARGET® study, the primary outcome 
occurred in 1423 patients (16.7%) in the telmisartan group, 
1412 patients (16.5%) in the ramipril group, and in 1386 
(16.3%) in the combination-therapy group.50 Telmisartan 
was non-inferior to ramipril, and the combination offered 
no additional protective effect. The results for the secondary 
outcome of death from cardiovascular causes, myocardial 
infarction or stroke were consistent with those of the primary 
outcome.
Even though individuals who were intolerant to ACE 
inhibitors had been excluded from the trial, 360 patients in 
the ramipril group stopped their medication because of cough 
compared with only 93 patients in the telmisartan group. 
Angioedema resulted in 25 patients discontinuing ramipril 
compared with 10 patients in the telmisartan group. Rates of 
cough and angioedema were also higher in the combination 
group than in the telmisartan group. In the combination 
group, significantly more patients stopped because of 
hypotensive symptoms, diarrhea, or renal impairment than 
in the ramipril group. The incidence of these events was also 
numerically higher than in the telmisartan group, although 
no statistics were reported for this comparison.
On the basis of the ONTARGET® results, telmisartan 
is the only ARB proven to have cardiovascular protective 
effects in a broad cross section of high-risk patients. It is as 
effective as ramipril but is associated with less angioedema 
and cough. The combination offers no additional efficacy 
advantage compared with the monotherapies. As the authors 
of the ONTARGET® publication state, the choice between 
telmisartan and ramipril ‘will depend on the preferences of 
the patients and physicians and the individual’s susceptibility 
to specific adverse events’.
In the TRANSCEND® study, telmisartan was well 
tolerated among patients who were unable to tolerate ACE 
inhibitors. Although the reduction in the primary outcome 
(which included hospitalizations for heart failure) with 
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significantly reduce the risk of the composite outcome 
of cardiovascular death, myocardial infarction, or stroke 
by 13%.127 Moreover, adherence to telmisartan was high 
and better in the comparison arm, in which patients received 
the best standard of care. It is reasonable to assume that the 
greater tolerability and treatment adherence observed with 
telmisartan in both ONTARGET® and TRANSCEND® will 
be of benefit for many patients who are likely to require 
life-long treatment.
The potential cerebroprotective efficacy of telmisartan 
was evaluated in the Prevention Regimen For Effectively 
avoiding Second Strokes (PRoFESS®) study.128 The 4-year 
study compared telmisartan and placebo on top of usual 
care, including antihypertensives to control blood pressure, 
in 20,000 patients with known prior ischemic stroke. 
The study had a 2 × 2 factorial design, with patients also 
receiving either aspirin plus dipyridamole extended release 
or clopidogrel alone. The primary outcome was time to 
recurrent stroke, while secondary outcomes included the onset 
of vascular events including bleeding events or CHF. There 
was non significant trend favoring telmisartan over usual care 
for the primary endpoint.129 Exploratory analyses indicate that 
after excluding the first 6 months of treatment, the incidence 
of recurrent stroke or major vascular events was significantly 
lower with telmisartan. The mean treatment period was 
2.5 years and a longer treatment period may have allowed 
the trends that were observed to become significant.
Conclusions
The pharmacologic features of telmisartan enable it to 
provide greater and more sustained antihypertensive efficacy 
than many other antihypertensive agents, and compared 
with other antihypertensive in other classes, telmisartan is 
well tolerated. Telmisartan in combination with HCTZ or 
amlodipine provides greater reductions in blood pressure 
than the respective monotherapies, and these combinations 
are well tolerated. The antihypertensive efficacy of telmis-
artan monotherapy and combinations should translate into 
increased protection against cardiovascular events. There 
is also growing evidence that telmisartan and ARBs have 
beneficial effects on various stages of the cardiovascular 
and renal continua that may not be solely explained by 
the lowering of blood pressure. ONTARGET® has shown 
that telmisartan provides similar cardiovascular protection 
to ramipril in high-risk patients, while being better toler-
ated and associated with greater treatment adherence; the 
latter property is likely to be important in the long-term 
management of cardiovascular risk.
The attributes of telmisartan and the clinical evidence 
of its efficacy suggest that it should be one of the preferred 
options for the treatment of hypertension in mild to moderate 
hypertensive patients and make it an attractive foundation for 
use in combination therapy. The findings of both ONTAR-
GET® and TRANSCEND® demonstrate that telmisartan pro-
vides a protective benefit when added to other therapies. Its 
effect on cardiovascular endpoints combined with its proven 
tolerability suggest that telmisartan could be considered as 
a potential treatment for patients with vascular disease or 
high-risk diabetes, irrespective of whether or not they can 
tolerate ACE inhibitors.
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